Thiết bị theo dõi glucose liên tục, bơm insulin và liệu pháp cung cấp insulin tự động cho bệnh tiểu đường typ 1: Cập nhật về tiềm năng lợi ích tim mạch

Centers for Disease Control and Prevention. National Diabetes Statistics Report website. 2022. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 2 July 2022. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778–86. American Diabetes Assocation. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17-s38. Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609–52. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. Diabetes Control and Complications Trial Writing Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125(2):177–88. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83–96. Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13(4):614–26. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21(2):81–5. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603. Beck RW, Bergenstal RM, Laffel LM, Pickup JC. Advances in technology for management of type 1 diabetes. Lancet. 2019;394(10205):1265–73. DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: international comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018;19(7):1271–5. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72. Cardona-Hernandez R, Schwandt A, Alkandari H, Bratke H, Chobot A, Coles N, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with type 1 diabetes. Data From the International Pediatric Registry SWEET. Diabetes Care. 2021;44(5):1176–84. van den Boom L, Karges B, Auzanneau M, Rami-Merhar B, Lilienthal E, von Sengbusch S, et al. Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care. 2019;42(11):2050–6. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25(2):99–111. Laffel LM, Kanapka LG, Beck RW, Bergamo K, Clements MA, Criego A, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2388–96. Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8(4):947–51. Irace C, Cutruzzolà A, Nuzzi A, Assaloni R, Brunato B, Pitocco D, et al. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(7):1056–61. Pease A, Szwarcbard N, Earnest A, Andrikopoulos S, Wischer N, Zoungas S. Glycaemia and utilisation of technology across the lifespan of adults with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). Diabetes Res Clin Pract. 2021;171:108609. Forlenza GP, Kushner T, Messer LH, Wadwa RP, Sankaranarayanan S. Factory-calibrated continuous glucose monitoring: how and why it works, and the dangers of reuse beyond approved duration of wear. Diabetes Technol Ther. 2019;21(4):222–9. Klonoff DC. FDA approves new Glucose Monitoring System. Diabetes Technol Ther. 1999;1(3):349. Meeting Report. FDA advisory panel votes to recommend non-adjunctive use of Dexcom G5 Mobile CGM. Diabetes Technol Ther. 2016;18(8):512–6. Sanchez P, Ghosh-Dastidar S, Tweden KS, Kaufman FR. Real-world data from the first U.S. commercial users of an implantable continuous glucose sensor. Diabetes Technol Ther. 2019;21(12):677–81. • Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, et al. Evaluation of accuracy and safety of the next-generation up to 180-day long-term implantable Eversense continuous glucose monitoring system: the PROMISE study. Diabetes Technol Ther. 2022;24(2):84–92. Prospective multicenter investigating accuracy and safety of 180 days of use of an implantable continuous glucose monitor. Results demonstrated accuracy and safety up to 180 days. The implantable continuous glucose monitor is a relatively novel concept and a significant advancement in continuous glucose monitoring. El-Laboudi AH, Godsland IF, Johnston DG, Oliver NS. Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring. Diabetes Technol Ther. 2016;18(12):806–12. Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Krӧger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61(3):539–50. Thomas MG, Avari P, Godsland IF, Lett AM, Reddy M, Oliver N. Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: pump or sensor first? A meta-analysis using pooled differences in outcome measures. Diabetes Obes Metab. 2021;23(11):2521–8. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367–77. Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32(8):1378–83. Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group. A randomized clinical trial assessing continuous glucose monitoring (CGM) use with standardized education with or without a family behavioral intervention compared with fingerstick blood glucose monitoring in very young children with type 1 diabetes. Diabetes Care. 2021;44(2):464–72. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371–8. Munshi M, Slyne C, Davis D, Michals A, Sifre K, Dewar R, et al. Use of technology in older adults with type 1 diabetes: clinical characteristics and glycemic metrics. Diabetes Technol Ther. 2022;24(1):1–9. Bratke H, Margeirsdottir HD, Assmus J, Njølstad PR, Skrivarhaug T. Does current diabetes technology improve metabolic control? A cross-sectional study on the use of insulin pumps and continuous glucose monitoring devices in a nationwide pediatric population. Diabetes Ther. 2021;12(9):2571–83. Roussel R, Riveline JP, Vicaut E, de Pouvourville G, Detournay B, Emery C, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021;44(6):1368–76. Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, et al. Benefits and barriers of continuous glucose monitoring in young children with type 1 diabetes. Diabetes Technol Ther. 2019;21(9):493–8. Cobry EC, Karami AJ, Meltzer LJ. Friend or foe: a narrative review of the impact of diabetes technology on sleep. Curr Diab Rep. 2022;22(7):283–90. Polonsky WH, Hessler D, Ruedy KJ, Beck RW. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care. 2017;40(6):736–41. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):6–10. Patton SR, Noser AE, Youngkin EM, Majidi S, Clements MA. Early initiation of dabetes devices relates to improved glycemic control in children with recent-onset type 1 diabetes mellitus. Diabetes Technol Ther. 2019;21(7):379–84. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, et al. 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S97-s112. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018;35(4):483–90. Hásková A, Radovnická L, Petruželková L, Parkin CG, Grunberger G, Horová E, et al. Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial. Diabetes Care. 2020;43(11):2744–50. • Visser MM, Charleer S, Fieuws S, De Block C, Hilbrands R, Van Huffel L, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397(10291):2275–83. Multicenter RCT comparing intermittently scanned continuous glucose monitoring and real-time continuous glucose monitoring in adults with type 1 diabetes. Results found that after 6 months of use, those using real-time continuous glucose monitoring had higher time in range, lower A1c, time in hypoglycemia, and fear of hypoglycemia. •• Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, et al. ISPAD clinical practice consensus guidelines 2018: diabetes technologies. Pediatr Diabetes. 2018;19 Suppl 27:302–25. Clinical practice guidelines regarding diabetes technology use in children, adolescents, and young adults with type 1 diabetes, developed by an international society for pediatric diabetes. Topics discussed include insulin pumps, continuous glucose monitors, sensor augmented pumps, and hybrid closed loop systems. Perez-Nieves M, Juneja R, Fan L, Meadows E, Lage MJ, Eby EL. Trends in U.S. insulin use and glucose monitoring for people with diabetes: 2009–2018. J Diabetes Sci Technol. 2021:19322968211028268. Kesavadev J, Saboo B, Krishna MB, Krishnan G. Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther. 2020;11(6):1251–69. Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318(14):1358–66. Marigliano M, Eckert AJ, Guness PK, Herbst A, Smart CE, Witsch M, et al. Association of the use of diabetes technology with HbA1c and BMI-SDS in an international cohort of children and adolescents with type 1 diabetes: the SWEET project experience. Pediatr Diabetes. 2021;22(8):1120–8. Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87–91. Miller KM, Beck RW, Foster NC, Maahs DM. HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D exchange clinic registry findings. Diabetes Technol Ther. 2020;22(9):645–50. Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019;56(9):973–80. Burckhardt MA, Smith GJ, Cooper MN, Jones TW, Davis EA. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes. Pediatr Diabetes. 2018;19(8):1459–66. Haynes A, Hermann JM, Miller KM, Hofer SE, Jones TW, Beck RW, et al. Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes. 2017;18(7):643–50. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25(7):765–74. Derosa G, Maffioli P, D’Angelo A, Salvadeo SA, Ferrari I, Fogari E, et al. Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). Endocr J. 2009;56(4):571–8. Jaser SS, Ellis D. Sleep in adolescents and young adults with type 1 diabetes: associations with diabetes management and glycemic control. Health Psychol Behav Med. 2016;4(1):49–55. Maahs DM, Hermann JM, Holman N, Foster NC, Kapellen TM, Allgrove J, et al. Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the U.S., Austria, and Germany. Diabetes Care. 2015;38(10):1876–82. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20. Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011;28(10):1158–67. Hermanides J, Devries JH. Sensor-augmented insulin pump more effective than multiple daily insulin injections for reducing HbA1C in people with poorly controlled type 1 diabetes. Evid Based Med. 2011;16(2):46–8. O’Connell MA, Donath S, O’Neal DN, Colman PG, Ambler GR, Jones TW, et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009;52(7):1250–7. Coronel-Restrepo N, Blanco VM, Palacio A, Ramírez-Rincón A, Arbeláez S, Duque V, et al. Real-world effectiveness and safety of sensor-augmented insulin pump therapy in adults with type 1 diabetes: long-term follow-up. Endocrinol Diabetes Nutr (Engl Ed). 2021;68(8):567–72. Tubili C, Pollakova D, Nardone MR, Di Folco U. Predictive low glucose suspend algorithm in real life: a five-year follow-up retrospective analysis. J Diabetes Sci Technol. 2021;15(6):1303–7. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012;14(3):205–9. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, Cengiz E, Wadwa RP, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care. 2018;41(10):2155–61. Pinsker JE, Leas S, Müller L, Habif S. Real world improvements in hypoglycemia in an insulin-dependent cohort with diabetes mellitus pre/post tandem basal-IQ technology remote software update. Endocr Pract. 2020. Abraham MB, Nicholas JA, Smith GJ, Fairchild JM, King BR, Ambler GR, et al. Reduction in hypoglycemia with the predictive low-glucose management system: a long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes Care. 2018;41(2):303–10. Verbeeten KC, Perez Trejo ME, Tang K, Chan J, Courtney JM, Bradley BJ, et al. Fear of hypoglycemia in children with type 1 diabetes and their parents: effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial. Pediatr Diabetes. 2021;22(2):288–93. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11):2672–82. Pease A, Lo C, Earnest A, Kiriakova V, Liew D, Zoungas S. Time in range for multiple technologies in type 1 diabetes: a systematic review and network meta-analysis. Diabetes Care. 2020;43(8):1967–75. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155–63. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, et al. Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther. 2018. Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, et al. Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatr Diabetes. 2022. Messer LH, Berget C, Vigers T, Pyle L, Geno C, Wadwa RP, et al. Real world hybrid closed loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes. 2019. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, et al. Real world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed loop use. Diabetes Obes Metabol. 2021. Berget C, Messer LH, Vigers T, Frohnert BI, Pyle L, Wadwa RP, et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes. 2019. Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One year clinical experience of the first commercial hybrid closed-loop. Diabetes Care. 2019. Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, et al. Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2021. Place J, Robert A, Ben Brahim N, Keith-Hynes P, Farret A, Pelletier MJ, et al. DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol. 2013;7(6):1427–35. Keith-Hynes P, Mize B, Robert A, Place J. The diabetes assistant: a smartphone-based system for real-time control of blood glucose. Electronics. 2014;3(4):609. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707–17. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019. • Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836–45. RCT comparing use of hybrid closed loop systems and sensor augmented insulin pumps in children with type 1 diabetes. Results showed greater time in range with use of the hybrid closed loop system. Ekhlaspour L, Schoelwer MJ, Forlenza GP, DeBoer MD, Norlander L, Hsu LJ, et al. Safety and performance of the Tandem t:slim X2 with Control-IQ automated insulin delivery system in toddlers and preschoolers. Diabetes Technol Ther. 2020. Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet (London, England). 2018;392(10155):1321–9. Forlenza GP, Lal RA. Current status and emerging options for automated insulin delivery systems. Diabetes Technol Ther. 2022. Benhamou PY, Franc S, Reznik Y, Thivolet C, Schaepelynck P, Renard E, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digit Health. 2019;1(1):e17–25. Cobry EC, Berget C, Messer LH, Forlenza GP. Review of the Omnipod® 5 automated glucose control system powered by Horizon™ for the treatment of type 1 diabetes. Ther Deliv. 2020;11(8):507–19. Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021. Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. Diabetes Care. 2022. Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21(6):45. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14-21. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010;33(7):1640–6. Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82. Lind M, Svensson AM, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2015;372(9):880–1. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144–74. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care. 2010;33(12):2573–9. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59(12):3216–22. Genuth SM, Backlund JY, Bayless M, Bluemke DA, Cleary PA, Crandall J, et al. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes. 2013;62(10):3561–9. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol. 1999;19(4):1014–9. Foreman YD, van Doorn W, Schaper NC, van Greevenbroek MMJ, van der Kallen CJH, Henry RMA, et al. Greater daily glucose variability and lower time in range assessed with continuous glucose monitoring are associated with greater aortic stiffness: the Maastricht study. Diabetologia. 2021;64(8):1880–92. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–69. Bancks MP, Carson AP, Lewis CE, Gunderson EP, Reis JP, Schreiner PJ, et al. Fasting glucose variability in young adulthood and incident diabetes, cardiovascular disease and all-cause mortality. Diabetologia. 2019;62(8):1366–74. Yapanis M, James S, Craig ME, O’Neal D, Ekinci EI. Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221–36. Snell-Bergeon JK, Roman R, Rodbard D, Garg S, Maahs DM, Schauer IE, et al. Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med. 2010;27(12):1436–42. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711–22. Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care. 2014;37(11):2974–81. Gimenez M, Lopez JJ, Castell C, Conget I. Hypoglycaemia and cardiovascular disease in Type 1 Diabetes. Results from the Catalan National Public Health registry on insulin pump therapy. Diabetes Res Clin Pract. 2012;96(2):e23–5. de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008;168(17):1867–73. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294–303. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55(12):3556–65. •• El Malahi A, Van Elsen M, Charleer S, Dirinck E, Ledeganck K, Keymeulen B, et al. Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2022;107(2):e570-e81. Prospective multicenter observational cohort study assessing the impact of nationwide reimbursement of real-time continuous glucose monitors in adults with T1D who were already using insulin pumps, thereby advancing management to sensor augmented insulin pump therapy. Results found those with >70% time in range had lower A1c; time in range independently associated with microvascular complications and diabetes-related hospitalizations. de Oliveira LT, Cardoso JN, Lopes C, Carreira AR, Rodrigues-Barros S, Vide-Escada A, et al. The effect of insulin pump therapy in retinal vasculature in type 1 diabetic patients. Eur J Ophthalmol. 2021;31(6):3142–8. Ferm ML, DeSalvo DJ, Prichett LM, Sickler JK, Wolf RM, Channa R. Clinical and demographic factors associated with diabetic retinopathy among young patients with diabetes. JAMA Netw Open. 2021;4(9):e2126126. Marchand L, Kawasaki-Ogita Y, Place J, Fayolle C, Lauton D, Boulet F, et al. Long-term effects of continuous subcutaneous insulin infusion on glucose control and microvascular cin patients with type 1 diabetes. J Diabetes Sci Technol. 2017;11(5):924–9. Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Nørgaard K. Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes. Diabetes Care. 2020;43(11):2882–5. Reid LJ, Gibb FW, Colhoun H, Wild SH, Strachan MWJ, Madill K, et al. Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin. Diabetologia. 2021;64(8):1725–36. Rosenlund S, Hansen TW, Andersen S, Rossing P. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study. Diabet Med. 2015;32(11):1445–52. Wysocka-Mincewicz M, Baszyńska-Wilk M, Gołębiewska J, Olechowski A, Byczyńska A, Hautz W, et al. Influence of metabolic parameters and treatment method on OCT angiography results in children with type 1 diabetes. J Diabetes Res. 2020;2020:4742952. Zabeen B, Craig ME, Virk SA, Pryke A, Chan AK, Cho YH, et al. Insulin pump therapy is associated with lower rates of retinopathy and peripheral nerve abnormality. PLoS ONE. 2016;11(4):e0153033. Kamrath C, Tittel SR, Kapellen TM, von dem Berge T, Heidtmann B, Nagl K, et al. Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health. 2021;5(1):17–25. Derosa G, Catena G, Scelsi L, D’Angelo A, Raddino R, Cosentino E, et al. Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). Diabetes Metab Res Rev. 2020;36(1):e3219. Steineck I, Cederholm J, Eliasson B, Rawshani A, Eeg-Olofsson K, Svensson AM, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ. 2015;350:h3234. Tubili C, Folco UD, Nardone MR, Clementi A. A single-center long-term continuous subcutaneous insulin infusion (CSII) experience: higher fractional use is associated with less diabetes complications. J Diabetes Sci Technol. 2017;11(5):1057–8. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605. Heier M, Stensæth KH, Brunborg C, Seljeflot I, Margeirsdottir HD, Hanssen KF, et al. Increased arterial stiffness in childhood onset diabetes: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2018;19(6):694–700. Rosenlund S, Theilade S, Hansen TW, Andersen S, Rossing P. Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. Acta Diabetol. 2014;51(6):955–62. Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–36. Faienza MF, Scicchitano P, Lamparelli R, Zaza P, Cecere A, Brunetti G, et al. Vascular and myocardial function in young people with type 1 diabetes mellitus: insulin pump therapy versus multiple daily injections insulin regimen. Exp Clin Endocrinol Diabetes. 2022;130(6):415–22. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2018. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40(8):994–9. Bergenstal RM, Gal RL, Connor CG, Gubitosi-Klug R, Kruger D, Olson BA, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med. 2017;167(2):95–102. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80. Klonoff DC, Wang J, Rodbard D, Kohn MA, Li C, Liepmann D, et al. A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J Diabetes Sci Technol. 2022:19322968221085273. Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm. Diabetes Technol Ther. 2019;21(8):462–9. Messer L, Berget C. PANTHER program. 2022. https://www.pantherprogram.org/. Accessed 12 July 2022. Alva S BR, Castorino K, Liljenquist D, Liu H, Kipnes M. Performance of the FreeStyle Libre 3 System. Presented at ADA 82nd Scientific Sessions; New Orleans, LA. June 5, 2022.